{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.3","upperLimit":"28.0","value":"23.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"}],"units":"Participants"}],"description":"OS is defined as the interval between the date of the first dose of study medication to the date of death due to any cause. For participants who did not die, time to death was censored at the time of last contact. The last date of contact was defined as the maximum date of any visit date or the survival follow-up date.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received pazopanib 800 milligrams (mg) once daily.","id":"OG000","title":"Pazopanib 800 mg"}],"paramType":"MEDIAN","populationDescription":"ATS Population","reportingStatus":"POSTED","timeFrame":"From the first dose of study medication to the earliest date of disease progression (PD) or death due to any cause (up to 3.460 years)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}